Cost analysis of overseas versus domestic vaccination of US-bound refugees
Joo, H.; Maskery, B.; Klosovsky, A.; Marquez, M.; Taher, S.; Dalal, W.; Weinberg, M.; Mitchell, T.
Show abstract
Context: To ensure healthy resettlement and protect US health security, the Vaccination Program for US-bound Refugees (VPR) offers some recommended vaccines to refugees overseas before resettlement to the United States. The selected vaccines and number of doses vary by country of departure. VPR was found to be cost-saving in 2018 but had since expanded to more sites. Objective: Assess VPR's current costs and impact on post-arrival domestic vaccination needs and costs. Setting and Participants: A model-based analysis of the Federal government costs for VPR and post-arrival (US) vaccination of resettled refugees separated across five regions: Africa, Asia, the Middle East and North Africa/Republic of Turkiye and Middle East, Europe, and the Americas using fiscal year 2024 data. Design: We quantified and compared full vaccination costs for refugees under two scenarios: (1) 'No VPR' and (2) 'VPR'. Refugees would receive no vaccines overseas and be fully vaccinated after US arrival under 'No VPR'. Under 'VPR', refugees receive one or two doses of selected vaccines overseas before completing vaccination schedules after arrival. Main Outcomes: Costs were reported in 2023 US dollars for 'VPR' and 'No VPR' scenarios and further subdivided by grouping countries/sites depending on whether the International Organization for Migration (IOM) provides vaccination services for refugees (IOM sites) versus non-IOM providers (non-IOM sites). Results: 'VPR' resulted in average net cost savings of $147 per person or $14.7 million per 100,000-refugee cohort compared to providing all vaccines after US arrival ('No VPR'). 'VPR' was cost-saving across most regions, except for IOM sites in Europe, where a net cost of $44 per person was observed. Net cost savings per person were highest for IOM sites in Africa ($333). Conclusions: VPR remains a cost-saving strategy, while protecting US-bound refugees' health and US health security by preventing disease outbreaks during resettlement.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery 95%
- Vaccinating Australia: How long will it take? 93%
- COVID-19 vaccine acceptance and its socio-demographic and emotional determinants: a multi-country cross-sectional study 93%
Similar papers in this journal
- Benefit-Risk Assessment Of COVID-19 Vaccine, Mrna (Mrna-1273) For Males Age 18-64 Years 92%
- Assessing the feasibility of Phase 3 vaccine trials against Marburg Virus Disease: a modelling study 92%
- Evaluation of statistical models of carriage to predict the impact of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in Nigeria 91%
Similar papers in this journal
- Modeling the Cost-Effectiveness of the Next-Generation COVID-19 mRNA-1283 Vaccine in the United States 94%
- The Potential Clinical Impact of Implementing Different COVID-19 Boosters in Fall 2022 in the United States 94%
- Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany 91%
Similar papers in this journal
- How can the public health impact of vaccination be estimated? 92%
- COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia 91%
- Transition to Endemic: Acceptance of Additional COVID-19 Vaccine Doses Among Canadian Adults in A National Cross-Sectional Survey 91%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.